Codexis (CDXS) Stock Price, News & Analysis

Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $2.66 to $2.74
• 50-Day Range: $2.36 to $3.33
• 52-Week Range: $1.90 to $6.08
• Volume: 514,430 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $246.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Codexis Stock Analysis - MarketRank™

Codexis scored higher than 75% of companies evaluated by MarketBeat, and ranked 245th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Codexis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Codexis is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Codexis is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Codexis has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.85% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Codexis has recently decreased by 2.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Codexis does not currently pay a dividend.

Dividend Growth

Codexis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.5 / 5
• Environmental Score: -3.67

Percentage of Shares Shorted

6.85% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Codexis has recently decreased by 2.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.40

News Sentiment

Codexis has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Codexis this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for CDXS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Codexis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Codexis is held by insiders.

Percentage Held by Institutions

78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CDXS Stock Analysis - Frequently Asked Questions

How have CDXS shares performed this year?

Codexis' stock was trading at $4.77 at the beginning of the year. Since then, CDXS stock has decreased by 42.8% and is now trading at $2.73.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $15.33 million during the quarter, compared to analyst estimates of $14.18 million. Codexis had a negative net margin of 113.67% and a negative trailing twelve-month return on equity of 105.83%.
Read the conference call transcript.

Who are Codexis' major shareholders?

Top institutional investors of Codexis include Opaleye Management Inc. (15.21%), Aberdeen Group plc (5.07%), Nantahala Capital Management LLC (4.87%) and Telemark Asset Management LLC (4.83%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald.
View institutional ownership trends.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDXS
• CIK: 1200375
• Web: www.codexis.com
• Phone: (650) 421-8100
• Fax: 650-421-8102
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Codexis: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +302.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.28 million
• Net Margins: -113.67%
• Pretax Margin: -113.61%
• Return on Equity: -105.83%
• Return on Assets: -46.06%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 5.82
• Quick Ratio: 5.70

Sales & Book Value

• Annual Sales: $59.35 million
• Price / Sales: 4.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 4.40

Miscellaneous

• Outstanding Shares: 90,270,000
• Free Float: 88,552,000
• Market Cap: $246.44 million
• Optionable: Optionable
• Beta: 2.54